{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000035","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-05-22T13:03:22+00:00","discovered_at":"2026-05-22T13:04:00.313188+00:00","generated_at":"2026-05-22T13:04:40.096530+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Oncolytics posts translational data from GOBLET/AWARE-1 at ASCO 2026 supporting pelareorep immune activation","bullets":["Data from GOBLET (advanced pancreatic cancer) and AWARE-1 (early-stage breast cancer) to be presented at ASCO 2026 May 29-June 2.","In pancreatic cancer, expansion of pre-existing TIL clones correlated with tumor volume reduction; mutant KRAS-specific T-cell clones expanded.","In breast cancer, increased antiviral/immune gene expression, CXCL13 induction, and tertiary lymphoid structure formation by imaging mass cytometry.","Abstract 'Influence of pelareorep on mutant KRAS-specific blood TIL clonal expansion' (No. 2664) presented May 30, 1:30-4:30 p.m. CT."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000035","json":"https://secwatch.observer/filing/0001129928-26-000035.json","markdown":"https://secwatch.observer/filing/0001129928-26-000035.md","text":"https://secwatch.observer/filing/0001129928-26-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000035/0001129928-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000035/oncy-20260522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T13:04:40.096530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001493152-26-026649","ticker":"VDTA","company_name":"Vertical Data Inc.","filed_at":"2026-06-01T20:47:23+00:00","headline":"Vertical Data launches Vertical Edge, a direct-ownership edge data center platform","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026649","json":"https://secwatch.observer/filing/0001493152-26-026649.json","markdown":"https://secwatch.observer/filing/0001493152-26-026649.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2033264/000149315226026649/0001493152-26-026649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2033264/000149315226026649/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001449794-26-000012","ticker":"EMYB","company_name":"Embassy Bancorp, Inc.","filed_at":"2026-06-01T20:37:17+00:00","headline":"Embassy Bancorp expands stock repurchase program by additional $5M","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001449794-26-000012","json":"https://secwatch.observer/filing/0001449794-26-000012.json","markdown":"https://secwatch.observer/filing/0001449794-26-000012.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/0001449794-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/emyb-20260601x8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026638","ticker":"XAIR","company_name":"Beyond Air, Inc.","filed_at":"2026-06-01T20:30:41+00:00","headline":"Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026638","json":"https://secwatch.observer/filing/0001493152-26-026638.json","markdown":"https://secwatch.observer/filing/0001493152-26-026638.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641631/000149315226026638/0001493152-26-026638-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641631/000149315226026638/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063531","ticker":"CTXR","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-06-01T20:30:19+00:00","headline":"Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063531","json":"https://secwatch.observer/filing/0001213900-26-063531.json","markdown":"https://secwatch.observer/filing/0001213900-26-063531.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/0001213900-26-063531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063530","ticker":"CTOR","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-06-01T20:30:18+00:00","headline":"Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063530","json":"https://secwatch.observer/filing/0001213900-26-063530.json","markdown":"https://secwatch.observer/filing/0001213900-26-063530.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/0001213900-26-063530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea0292903-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001636282-26-000075","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-06-01T20:01:39+00:00","headline":"Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000075","json":"https://secwatch.observer/filing/0001636282-26-000075.json","markdown":"https://secwatch.observer/filing/0001636282-26-000075.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/0001636282-26-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/syre-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063481","ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2026-06-01T20:01:27+00:00","headline":"Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063481","json":"https://secwatch.observer/filing/0001213900-26-063481.json","markdown":"https://secwatch.observer/filing/0001213900-26-063481.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/0001213900-26-063481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/ea0292876-8k_oruka.htm"},"side_by_side_evidence":null},{"accession":"0001606268-26-000032","ticker":"VIASP","company_name":"Via Renewables, Inc.","filed_at":"2026-06-01T19:06:57+00:00","headline":"Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001606268-26-000032","json":"https://secwatch.observer/filing/0001606268-26-000032.json","markdown":"https://secwatch.observer/filing/0001606268-26-000032.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/0001606268-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/spke-20260601.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}